126 related articles for article (PubMed ID: 37439379)
21. Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Taguchi J; Shimizu Y; Ariga S; Goda T; Ohhara Y; Honma R; Noguchi T; Takeuchi S; Kinoshita I; Amano T; Mizumachi T; Kano S; Takahara M; Abe T; Homma A; Dosaka-Akita H
Int J Clin Oncol; 2021 Jan; 26(1):51-58. PubMed ID: 32996023
[TBL] [Abstract][Full Text] [Related]
22. Treatment Package Time in Node-Positive Cutaneous Head and Neck Squamous Cell Carcinoma.
Daniels CP; Bressel M; Corry J; Cole A; Chua MS; Tiong A; Hirshoren N; Dixon B; McDowell L
Pract Radiat Oncol; 2020; 10(1):29-35. PubMed ID: 31606546
[TBL] [Abstract][Full Text] [Related]
23. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
24. Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly?
Haehl E; Rühle A; David H; Kalckreuth T; Sprave T; Stoian R; Becker C; Knopf A; Grosu AL; Nicolay NH
Radiat Oncol; 2020 Feb; 15(1):31. PubMed ID: 32019576
[TBL] [Abstract][Full Text] [Related]
25. Split-course hypofractionated radiotherapy for aged and frail patients with head and neck cancers. A retrospective study of 75 cases.
Benhmida S; Sun R; Gherga E; Hammoud Y; Rouvier J; Mauvais O; Bockel S; Louvrier A; Lebbad A; Bontemps P; Ortholan C; Bourhis J; Lestrade L; Sun XS
Cancer Radiother; 2020 Dec; 24(8):812-819. PubMed ID: 33144061
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of hypofractionated radiotherapy in patients with non-melanoma skin cancer: Results of a systematic review.
Gunaratne DA; Veness MJ
J Med Imaging Radiat Oncol; 2018 Jun; 62(3):401-411. PubMed ID: 29524319
[TBL] [Abstract][Full Text] [Related]
27. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
[TBL] [Abstract][Full Text] [Related]
28. Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy.
Marín-Jiménez JA; Oliva M; Peinado Martín P; Cabezas-Camarero S; Plana Serrahima M; Vázquez Masedo G; Lozano Borbalas A; Cabrera Martín MN; Esteve A; Iglesias Moreno MC; Vilajosana Altamis E; Arribas Hortigüela L; Taberna Sanz M; Pérez-Segura P; Mesía R
Front Oncol; 2022; 12():953020. PubMed ID: 35936723
[TBL] [Abstract][Full Text] [Related]
29. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
30. Cyclical hypofractionated radiotherapy also known as "QUAD Shot" alone using intensity-modulated radiotherapy for squamous cell carcinoma of the parotid gland in an 85-year-old patient with multiple comorbidities.
Kil WJ; Camphausen K
Head Neck; 2017 Apr; 39(4):E55-E60. PubMed ID: 28170130
[TBL] [Abstract][Full Text] [Related]
31. "Christie Regimen" palliative radiotherapy in advanced head-and-neck cancer: A single-center experience.
Srivastava A; Adhikari N; Sonkar DR; Singh K; Rathi AK
J Cancer Res Ther; 2021; 17(1):88-93. PubMed ID: 33723137
[TBL] [Abstract][Full Text] [Related]
32. Activity of weekly paclitaxel-cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors.
Bernad IP; Trufero JM; Urquizu LC; Pazo Cid RA; de Miguel AC; Agustin MJ; Lanzuela M; Antón A
Clin Transl Oncol; 2017 Jun; 19(6):769-776. PubMed ID: 28120324
[TBL] [Abstract][Full Text] [Related]
33. Age is not a predictor of prognosis in metastatic cutaneous squamous cell carcinoma of the head and neck.
Smith JA; Virk S; Palme CE; Low TH; Ch'ng S; Gupta R; Gao K; Clark J
ANZ J Surg; 2018 Apr; 88(4):E273-E277. PubMed ID: 29611361
[TBL] [Abstract][Full Text] [Related]
34. Effect of definitive hypo-fractionated radiotherapy concurrent with weekly cisplatin in locally advanced squamous cell carcinoma of the head and neck.
Abdelhafiz N; Mahmoud D; Gad M; Essa H; Morsy A
J Med Life; 2023 May; 16(5):743-750. PubMed ID: 37520484
[TBL] [Abstract][Full Text] [Related]
35. Surgical management of recurrent cutaneous squamous cell carcinoma of the head and neck after definitive surgery and radiotherapy.
Toppi J; Tham YS; Webb A; Henderson MA; Rischin D; Magarey MJR
ANZ J Surg; 2020 Jul; 90(7-8):1391-1395. PubMed ID: 32627359
[TBL] [Abstract][Full Text] [Related]
36. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
[TBL] [Abstract][Full Text] [Related]
37. The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck.
Suntharalingam M; Haas ML; Conley BA; Egorin MJ; Levy S; Sivasailam S; Herman JM; Jacobs MC; Gray WC; Ord RA; Aisner JA; Van Echo DA
Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):49-56. PubMed ID: 10758304
[TBL] [Abstract][Full Text] [Related]
38. HYpofractionated, dose-redistributed RAdiotherapy with protons and photons to combat radiation-induced immunosuppression in head and neck squamous cell carcinoma: study protocol of the phase I HYDRA trial.
Elbers JBW; Gunsch PA; Debets R; Keereweer S; van Meerten E; Zindler J; van Norden Y; Hoogeman MS; Verduijn GM; Kroesen M; Nout RA
BMC Cancer; 2023 Jun; 23(1):541. PubMed ID: 37312053
[TBL] [Abstract][Full Text] [Related]
39. Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma.
Jacinto AA; Batalha Filho ES; Viana LS; De Marchi P; Capuzzo RC; Gama RR; Boldrini Junior D; Santos CR; Pinto GDJ; Dias JM; Canton HP; Carvalho R; Radicchi LA; Bentzen S; Zubizarreta E; Carvalho AL
BMC Cancer; 2018 Oct; 18(1):1026. PubMed ID: 30352576
[TBL] [Abstract][Full Text] [Related]
40. Use of
Rudžianskas V; Korobeinikova E; Rudžianskienė M; Jaselskė E; Adlienė D; Šedienė S; Kulakienė I; Padervinskis E; Jurkienė N; Juozaitytė E
Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30544718
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
